Beat of the Week

(Honorable Mention)

AP probes a pharmaceutical fortune, dispersed in a global labyrinth

Amid reports of an opioid settlement, an investigation shows the myriad ways that the Sackler family which owns Purdue Pharma in a web of companies and trusts, many of them overseas.Adam Geller, national writer, New York. Geller reviewed court papers, securities filings and documents leaked from an exclusive Bermuda law firm. He found that the family has shielded its wealth in ways that could complicate efforts to recover the money in opioid settlements.

https://www.washingtonpost.com/national/health-science/familys-web-makes-it-hard-to-track-cash-from-opioid-maker/2019/08/29/80d4f43e-ca99-11e9-9615-8f1a32962e04_story.html

Beat of the Week

(Honorable Mention)

Pricey drugs overwhelm Medicare safeguard

Ricardo Alonso-Zaldivar, reporter, Washington, D.C., for using cost figures obtained exclusively from Medicare actuaries to describe how the program’s safeguard for consumers with high drug costs had turned into a way for pharmaceutical companies to collect billions ...

Best of the Week — First Winner

Pro-painkiller echo chamber shaped policy amid drug epidemic

Combine the capabilities of The Associated Press and the Center for Public Integrity, and this is what you can get: A two-part blockbuster that exposed the efforts of the opioid industry and allied groups to stymie limits on the use of its powerful drugs, and detailed how they spent more than $880 million on lobbying and political contributions over the past decade.

The genesis of the project was a conversation between Tom Verdin, editor of AP’s state government team, and Geoff Mulvihill, a member of that team. Mulvihill, based in Mount Laurel, N.J., has covered the opioid crisis sweeping the nation, and the two hit upon the idea of trying to determine the extent of the pharmaceutical industry’s exerting influence in state legislatures across the country.

Beat of the Week

(Honorable Mention)

Opioids scoop: Reporters expose Italian probe of Purdue’s foreign affiliate

for breaking the news that executives with the international arm of Purdue Pharma were caught up in a criminal investigation in Italy alleging they paid a doctor to help sell more opioids in the country. It’s the first known criminal case outside of the U.S. involving employees with the pharmaceutical empire owned by the Sackler family, and the the first in an investigative series about the spread of opioids overseas. The reporters found that the doctor wrote scientific studies and organized conferences to promote opioids as safe and effective for chronic pain patients – the same tactics that experts and attorneys general say Purdue and other companies used in the U.S. that laid the foundation for the addiction crisis.https://bit.ly/2EG0sOZhttps://www.apnews.com/GlobalOpioids

Beat of the Week

(Honorable Mention)

AP analysis: Manufacturers of generic opioids fueled crisis

delivered a fast, smart follow-up after U.K.-based Mallinckrodt Pharmaceuticals announced a U.S. settlement over its role in the opioid epidemic. The team’s analysis revealed that Mallinckrodt and one other generic drug manufacturer were responsible for the vast majority of high-dosage prescription painkillers – billions of generic pills – distributed throughout the U.S. during the height of the opioid epidemic. https://bit.ly/2IoXuQG

Beat of the Week

(Honorable Mention)

AP: Vaccine production hampered by pharma patents

broke the news that governments and aid groups worldwide, along with the World Health Organization, are calling on pharmaceutical companies to share their vaccine information more broadly to meet a yawning global shortfall and inequities in vaccine distribution. The companies say they can only sign deals on a one-on-one basis to protect their intellectual property, but critics believe they have broader obligations because they took taxpayer money to develop the vaccines. The London-based correspondents found three factories on three continents whose owners say they could start producing hundreds of millions of COVID-19 vaccines on short notice if only they had the blueprints and technical know-how. A former director of chemistry at Moderna confirmed that, and photographer Al-emrun Garjon delivered photos of a high-tech factory in Bangladesh producing vaccine at about 25% of its capacity.After the AP story ran, the head of WHO, citing a health emergency, called for patent rights to be waived until the end of the pandemic so that vaccine supplies can be dramatically increased. https://bit.ly/38vMgXI

Beat of the Week

(Honorable Mention)

AP reveals the inside story of glaring vaccine inequity globally

turned a year spent tracking global vaccine distribution into an authoritatively sobering assessment: A grotesque vaccine disparity has emerged between rich and poor countries, at a scale even experts who’d warned of inequitable distribution hadn’t envisioned.Tapping connections worldwide, including officials and bankers who participated in key behind-the-scenes vaccine discussions in Europe and the U.S., the AP trio found that negotiators acknowledged they could have made bigger demands of pharmaceutical companies — but that it was now too late. They also learned that COVAX, the United Nations’ vaccine procurement effort, simply did not have the cash to make deals when rich countries were buying up all the supplies, while pleas for funding to the World Bank and others were rejected.What emerged was a richly reported piece that lays out the specific reasons behind the glaring disparities and contradicts the sweeping pandemic rhetoric about global solidarity: European and American officials deeply involved in bankrolling and distributing the vaccines told the AP there was no thought of how to handle the situation globally. Instead, they jostled for their own domestic use. https://aplink.news/wjg

Beat of the Week

(Honorable Mention)

DEA’s No. 2 quits amid reports of previous consulting work for Big Pharma

AP broke the story of how the U.S. Drug Enforcement Administration’s second-in-command quietly stepped down after they had reported that he had previously done extensive consulting work for pharmaceutical companies, including the drug maker that became the face of the opioid crisis, Purdue Pharma.Read more